FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to an antibody which specifically binds to PD-1 (protein 1 of programmable cell death). Also disclosed is an isolated cell line and a host cell producing said antibody; a nucleic acid encoding said antibody; an expression vector; pharmaceutical composition and kit containing said antibody. Disclosed is a method of producing said antibody; method of treatment and a method for increasing immunogenicity or therapeutic effect using said antibody.
EFFECT: invention has the ability effectively treat diseases associated with PD-1.
41 cl, 16 ex, 33 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| METHODS OF TREATING CHRONIC PAIN | 2009 |
|
RU2522493C2 |
| ANTIBODIES DIRECTED TO PROTEIN OF PROGRAMMED DEATH OF CELL-1 (PD-1) | 2014 |
|
RU2723050C2 |
| TREATMENT OF INTERSTITIAL CYSTITIS | 2008 |
|
RU2570559C2 |
| HUMAN VISTA ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2746994C2 |
| SPECIFIC LINKING AGENTS AGAINST B7-H1 | 2010 |
|
RU2571204C2 |
| SPECIFIC BINDING AGENTS AGAINST B7-H1 | 2010 |
|
RU2706200C2 |
| ANTI-PDL-1 ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND USE | 2017 |
|
RU2693661C2 |
| COMPOSITIONS OF ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2772781C2 |
| METHODS OF OSTEOARTHRITIS PAIN MANAGEMENT BY ADMINISTRATION OF NERVE GROWTH FACTOR ANTAGONIST AND COMPOSITIONS CONTAINING IT | 2006 |
|
RU2429013C2 |
